Vera Therapeutics received priority review from the FDA for its biologics license application for atacicept to treat adults ...
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback